OS for relapsed and refractory (R/R) patients with MTCL and MNKCL stratified by histological subtype comparing second-line treatment with CC or a “novel” SA, which includes EM, ADC, AF, SMI, or a mAb. Kaplan-Meier curves show OS estimates since start of second-line treatment for patients with PTCL-NOS (A), AITL (B), ENKTCL (C), ALK⁺ ALCL (D) and, ALK^– ALCL (E). Results depicted apply to the global data set of 763 patients for whom information on the start of second-line treatment was available. P values calculated by log-rank test. mAb, monoclonal antibody.